OncoMed Pharmaceuticals, Inc. announced unaudited earnings results for the fourth quarter and year ended December 31, 2018. For the quarter, the company reported total revenue of $10,184,000 against $20,640,000 for the same period a year ago. Loss from operations was $5,016,000 against income from operations of $8,245,000 for the same period a year ago. Net loss was $4,666,000 compared to net income of $9,463,000 a year ago. Basic and diluted net loss per common share was $0.12 compared to basic and diluted net income per share of $0.25 a year ago. For the year, the company reported total revenue of $44,421,000 against $38,154,000 for the same period a year ago. Loss from operations was $10,045,000 against $40,973,000 for the same period a year ago. Net loss was $8,101,000 compared to $39,062,000 a year ago. Basic and diluted net loss per common share was $0.21 compared to $1.04 a year ago.